Erratum to: Breast Cancer Res Treat (2012) 134:511–517 DOI 10.1007/s10549-012-2079-4
Figure 1c in the original publication had nuclear lamin B controls inserted in both the cytoplasm and nucleus sets. The revised Fig. 1c show the correct GAPDH controls. The authors regret this error.
a Proposed hypothesis: Small molecule inhibitors of BRCT(BRCA1)–phosphoprotein interaction will increase the sensitivity of cancer cells to DNA damage based therapeutics. The inhibitor is represented as a red X. b Competitive inhibition curves for BRCT(BRCA1) inhibitor peptides 1 (Ac-pSPTF-CO2H) and 2 (Ac-R10 G-pSPTF-CO2H). c IP and IB studies with and without the BRCT inhibitor 2 in the presence and absence of IR-induced DNA damage
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s10549-012-2079-4.
Rights and permissions
About this article
Cite this article
Pessetto, Z.Y., Yan, Y., Bessho, T. et al. Erratum to: Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Breast Cancer Res Treat 155, 613 (2016). https://doi.org/10.1007/s10549-016-3702-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-016-3702-6